Rituximab therapy for rheumatoid arthritis / 中国实用内科杂志

ABSTRACT

The mouse/human chimeric anti-CD20 Rituximab(Moab mabthera) can avoid acting on stem cells,pre-B cells and plasma cells;and selectively targets on B cells which have CD20 on their surfaces.Rituximab has been shown to reduce signs and symptoms and to slow the progression of structural damage in adult patients with moderately-to severely-active rheumatoid arthritis in randomised controlled trials and now in the United States has been approved for use in combination with methotrexate(MTX)for the treatment of rheumatoid arthritis by the US Food and Drug Administration.